Mesoblast Ltd ADR MESO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award
Mesoblast Showcased at ASX Premier Investor Day Event
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
Mesoblast Board Changes
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Mesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast Financial Results and Corporate Update Webcast
Trading Information
- Previous Close Price
- $11.64
- Day Range
- $11.02–11.56
- 52-Week Range
- $11.02–21.50
- Bid/Ask
- $4.50 / $15.01
- Shares Outstanding
- 129.85M
- Market Cap
- $1.45B
- Volume/Avg
- 262,559 / 239,596
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 108
- Website
- https://www.mesoblast.com
Valuation
Metric | MESO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.66 |
Price/Sales | 12.53 |
Price/Cash Flow | — |
Price/Earnings
MESO
Financial Strength
Metric | MESO |
|---|---|
Quick Ratio | 1.30 |
Current Ratio | 2.43 |
Interest Coverage | — |
Quick Ratio
MESO
Profitability
Metric | MESO |
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
MESO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Rp#WC#p | LOCK|s>qSs | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|$><^K? | LOCK|<<y? | $96B | |||
| Moderna Inc MRNA | LOCK|Mb!?l!% | LOCK|#&# | $81B | |||
| argenx SE ADR ARGX | LOCK|C>kNCT | LOCK|?$c | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|FHd>Q? | LOCK|@# | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|mKJRtwCr | LOCK|BGwgK | $30B | |||
| Incyte Corp INCY | LOCK|V?FrwL | LOCK|l%g | $24B | |||
| BioNTech SE ADR BNTX | LOCK|%?<LVPf | LOCK|?W | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Sf&rr? | LOCK|<S@s | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|pb?%@nq | LOCK|@y | $15B |